Roger Gregory, PhD, Professor of Chemistry and Biochemistry, Kent State University, has been working with Arch Therapeutics since late 2011. He has provided expertise in product formulation and the relationship between the structure and properties of peptides. Dr. Gregory is a physical biochemist with over 30 years of experience in protein chemistry and analysis. His research interests include protein dynamics, protein hydration, and protein-solvent interactions. He recently returned to the Kent State faculty after serving over seven years as Chair of the Department of Chemistry. As Chair, he helped establish core facilities in genomics, proteomics, bioimaging and 3D visualization. Dr. Gregory earned his BSc and PhD in Biochemistry from the University of Sheffield, England, and performed his postdoctoral work in Protein Chemistry at the University of Minnesota.

Dr. Denman started advising Arch Therapeutics in 2012. He is a Massachusetts General Hospital Anesthesiologist, Clinical Trial Investigator and past Chief Medical Officer of Covidien and GE Healthcare.

Dr. Denman received his medical training in the United Kingdom, completing residency at St. Bartholomew’s Hospital in London, followed by a fellowship at Massachusetts General Hospital, remaining on staff. In 2000 he became Chief of Pediatric Anesthesia at the Floating Hospital for Children in Boston. During his full-time medical practice he was involved in multiple clinical trials and development of pharmaceuticals and devices. He filed and was awarded several patents while focusing on solutions for unmet clinical needs.

In 2003, he began his career at Tyco Healthcare, now Covidien, becoming the Chief Medical Officer and VP for Medical Affairs in 2007. He guided development and implementation of the medical functions throughout Covidien, built a medical affairs, clinical affairs, healthcare economics and reimbursement team; focused these functions on ensuring compliance with new regulations and driving the medical voice into all aspects of the business. From 2010 to 2012, he was the Chief Medical Officer at GE Healthcare. In this role he strove to ensure a patient-centered culture while focusing on healthcare providers and his team was embedded in all facets of the business; R&D, clinical trials, training, compliance, business development and risk management.

He continues a clinical practice at Massachusetts General Hospital and an academic affiliation at Harvard Medical School, both in Boston. He continues to publish and has recently been granted several more patents. He is co-leader of an annual mission to Vietnam where he provides care to children and medical teaching to those who care for children.

John Richards, DPhil., who started advising Arch Therapeutics in 2016, brings over 30 years of pharmaceutical industry and peptide chemistry experience. Since 2009, he has been Vice President of Global Pharmaceutical Development at The Medicines Company, responsible for CMC development and manufacturing of all the company’s products, including the very large scale program for the peptide-based anticoagulant, Angiomax®. He has extensive experience leading CMC programs which have resulted in the successful filing and approval of drugs and biologics in the United States, European Union and other territories.

Previous roles included Director of Process Development at ImmuLogic Pharmaceutical Corporation, where he was responsible for the design, construction and operation of a multi-train peptide manufacturing facility, and Manager of Peptide Synthesis at UK start-up Cambridge Research Biochemicals and its acquirer ICI Pharmaceuticals, where he contributed to pioneering activities in the 1980's to manufacture cGMP peptides at contract manufacturers for pharmaceutical use. 

He earned his doctorate developing protecting groups for use in peptide synthesis at The University of Oxford. While performing his Post-Doctoral work in the Laboratory of Molecular Biology, Cambridge, UK, he was a member of Dr. Robert Sheppard's team that developed the Fmoc-solid phase method of peptide synthesis.

Dr. Daniel Kapp, an advisor to Arch as of 2019, is a Board Certified Plastic Surgeon. He is currently the Chief of Plastic Surgery at Palm Beach Gardens Medical Center where he previously served as the Chief of Surgery. Dr. Kapp is also the Medical Director of the Wound Healing Center at Jupiter Medical Center. He has served as an advisor to a number of pharmaceutical and medical device manufacturers and is currently a key Scientific Advisor to Recros Medica. Dr. Kapp was a founding partner and has served on the Medical Advisory Board of MDLive, one of the nation’s largest telemedicine providers since its 2009 inception. He is a partner and founder of Injecture and Conjecture, which focuses on insurance for cosmetic applications. Kapp has been involved in product development from design to launch. Dr. Kapp is a graduate of the University of Virginia. He completed medical school at the University of South Florida and Plastic Surgery Residency at the Ohio State University. He was the Anastasi Fellow in Plastic Surgery at Boston University.

Dr. Ellis-Behnke is the inventing cofounder and a scientific advisor to Arch Therapeutics. His discovery of the immediate hemostasis technology while he was at MIT led to the founding of the company. He holds 10 U.S. patents for multiple discoveries that use nanotechnology to help repair the body, ranging from immediate hemostasis; repairing the optic nerve and demonstrating the reversal of blindness; preserving stem cells; and immobilizing cancer stem cells. Dr. Ellis-Behnke holds affiliate faculty positions at MIT and the University of South Florida Morgani College of Medicine. From 2010 to 2015 he was Director of the Nanotechnology Translational Think Tank in the Mannheim Medical Faculty of the University of Heidelberg in Germany; from 2004 to 2010 he was in the Faculty of Medicine at the University of Hong Kong first as a Research Associate from 2004 to 2006, then as Associate Professor and concurrently Associate Director of the Technology Transfer Office from 2007 to 2010. Prior to returning to MIT to pursue his PhD in 1998, he held various management positions including Senior Vice President of Huntingdon, a public company for pharmaceutical testing and consulting services. In 1995, he became co-founder/CEO of one of the first internet companies in the world to do online commerce. Dr. Ellis-Behnke received his PhD from MIT in Neuroscience in 2003; his BS from Rutgers in Agricultural Sciences in 1984 and a diploma from Harvard Business School’s Advanced Manager’s Program in 1995. From 2006 to 2015 he was the Associate Editor/Neurology for Nanomedicine: Nanotechnology, Biology & Medicine. He is a member of the National Academy of Inventers and a life member of the International Society of Nanomedicine.

Steve Schwaitzberg, MD, FACS, is an advisor to Arch, bringing his expertise in surgery, clinical trials, and biomaterials for hemostasis and sealing. He is Professor of and Chairman the Department of Surgery for the University at Buffalo - Jacobs School of Medicine and Biomedical Sciences. Formerly he was the Chief of Surgery at Cambridge Health Alliance, adjunct professor at Tufts University, and Professor of surgery at Harvard Medical School. He is Past President of the Society of American Gastrointestinal Endoscopic Surgeons (SAGES), a world-class laparoscopic surgical association.

A key opinion leader, Dr. Schwaitzberg has a distinguished reputation in surgery. He was initially trained as a trauma and surgical infection expert and then became an early leader in the minimally invasive surgery (MIS) revolution. Dr. Schwaitzberg is an innovator who teaches surgical technique around the world. He has served in key leaderships positions in major surgical organizations and received international recognition as a leader in technology in the operating room and for the introduction of novel MIS technology.

Dr. Schwaitzberg is a seasoned clinical researcher who also served as the Chairman of the Tufts University School of Medicine and Medical Center institutional review Board. He has a deep interest in technology development. He is widely published and has been invited to present and teach courses around the world for over 25 years. Dr. Schwaitzberg earned an MD from Baylor College of Medicine, a MA from Harvard medical School and a BA in biology from The Johns Hopkins University.

Dr. Austen, an advisor to Arch as of 2020, is Chief of the Plastic and Reconstructive Surgery Division and Chief of Burn Surgery at Massachusetts General Hospital; Professor of Surgery at Harvard Medical School; Director of the Aesthetic and Reconstructive Breast Fellowship Program; and Mass General Trustee Chair of Plastic and Reconstructive Surgery. He received his undergraduate degree at Princeton followed by his medical degree at Harvard Medical School. Dr. Austen trained in General Surgery and Plastic Surgery at the Harvard Medical School and completed a Fellowship in Craniofacial Surgery at the Royal Children’s Hospital in Melbourne, Australia. Dr. Austen is a member of numerous societies including the Society of University Surgeons, the American College of Surgeons, the American Association of Plastic Surgeons, the ASPS, and the Migraine Surgery Council. 

Dr. Austen has a diverse clinical practice that spans aesthetic and reconstructive surgery. He is an authority in the new field of the surgical treatment of migraine headaches. The focus of his laboratory is on translational research, particularly in fat regeneration, vascular biology, and device development.  

Dr Austen has a long history of innovation in outcomes and basic science. He is founder of Cytrellis Bio-Systems and Auragen Aesthetics, both companies based on his innovations. He has authored more than 100 papers and holds numerous patents. Dr. Austen has won numerous awards including Teacher of the Year in Plastic Surgery training program at the Harvard Medical School and Experimental Paper of the Year 2015 in Plastic and Reconstructive Surgery, the Journal of the American Society of Plastic Surgeons.